{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:58:11Z","timestamp":1711673891083},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02335-3","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:02:52Z","timestamp":1709539372000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway"],"prefix":"10.1007","volume":"41","author":[{"given":"Aydemir","family":"ASDEM\u0130R","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aykut","family":"\u00d6ZG\u00dcR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2335_CR1","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, diagnosis, Treatment options, and alternative approaches. Molecules. 2022;27:5730.","journal-title":"Molecules"},{"key":"2335_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The diagnosis and treatment of prostate Cancer: a review. JAMA. 2017;317:2532\u201342.","journal-title":"JAMA"},{"key":"2335_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, Morgan TM, Carlsson SV. 2022 update on prostate Cancer epidemiology and risk Factors-A systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"2335_CR4","first-page":"2780","volume":"11","author":"S Mumuni","year":"2023","unstructured":"Mumuni S, O\u2019Donnell C, Doody O. The risk factors and screening uptake for prostate Cancer: a scoping review. Healthc (Basel). 2023;11:2780.","journal-title":"Healthc (Basel)"},{"key":"2335_CR5","doi-asserted-by":"publisher","first-page":"1159557","DOI":"10.3389\/fonc.2023.1159557","volume":"13","author":"AK Taylor","year":"2023","unstructured":"Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023;13:1159557.","journal-title":"Front Oncol"},{"key":"2335_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MOU.0000000000000784","volume":"30","author":"NA Huebner","year":"2020","unstructured":"Huebner NA, Shariat SF, Resch I, Gust K, Kramer G. The role of taxane-based chemotherapy in the treatment of prostate cancer. Curr Opin Urol. 2020;30:527\u201333.","journal-title":"Curr Opin Urol"},{"key":"2335_CR7","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/annonc\/mdx348","volume":"28","author":"DI Quinn","year":"2017","unstructured":"Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017;28:2658\u201369.","journal-title":"Ann Oncol"},{"key":"2335_CR8","doi-asserted-by":"publisher","first-page":"e2034633","DOI":"10.1001\/jamanetworkopen.2020.34633","volume":"4","author":"UN Vaishampayan","year":"2021","unstructured":"Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, Smith D, Jasti P, Dobson K, Dickow B, Heath EI, Semaan L, Cher ML, Fontana JA, Chinni S. Clinical efficacy of Enzalutamide vs Bicalutamide Combined with Androgen Deprivation Therapy in Men with metastatic hormone-sensitive prostate Cancer: a Randomized Clinical Trial. JAMA Netw Open. 2021;4:e2034633.","journal-title":"JAMA Netw Open"},{"key":"2335_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.clgc.2022.11.017","volume":"21","author":"N Shore","year":"2023","unstructured":"Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, Cullberg M, Teruel CF, Morris T. A phase I study of Capivasertib in Combination with Abiraterone acetate in patients with metastatic castration-resistant prostate Cancer. Clin Genitourin Cancer. 2023;21:278\u201385.","journal-title":"Clin Genitourin Cancer"},{"key":"2335_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1200\/JCO.1994.12.4.683","volume":"12","author":"A Sella","year":"1994","unstructured":"Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 1994;12:683\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2335_CR11","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421\u20138.","journal-title":"Cancer Res"},{"key":"2335_CR12","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-10-4336","volume":"71","author":"J Shi","year":"2011","unstructured":"Shi J, Zhou Y, Huang HC, Mitchison TJ. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res. 2011;71:4518\u201326.","journal-title":"Cancer Res"},{"key":"2335_CR13","doi-asserted-by":"publisher","first-page":"564108","DOI":"10.3389\/fphar.2020.564108","volume":"11","author":"NN Mohamad Anuar","year":"2020","unstructured":"Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A. Clinical review: Navitoclax as a pro-apoptotic and anti-fibrotic Agent. Front Pharmacol. 2020;11:564108.","journal-title":"Front Pharmacol"},{"key":"2335_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/1871520615666150821093747","volume":"16","author":"A \u00d6zg\u00fcr","year":"2016","unstructured":"\u00d6zg\u00fcr A, Tutar Y. Heat shock protein 90 inhibition in Cancer Drug Discovery: from Chemistry to Futural Clinical Applications. Anticancer Agents Med Chem. 2016;16:280\u201390.","journal-title":"Anticancer Agents Med Chem"},{"key":"2335_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2174\/1389201017666161031105815","volume":"17","author":"M G\u00fcmus","year":"2016","unstructured":"G\u00fcmus M, Ozgur A, Tutar L, Disli A, Koca I, Tutar Y, Design. Synthesis, and evaluation of heat shock protein 90 inhibitors in human breast Cancer and its metastasis. Curr Pharm Biotechnol. 2016;17:1231\u201345.","journal-title":"Curr Pharm Biotechnol"},{"key":"2335_CR16","doi-asserted-by":"publisher","first-page":"112063","DOI":"10.1016\/j.ejmech.2020.112063","volume":"189","author":"TEMM Costa","year":"2020","unstructured":"Costa TEMM, Raghavendra NM, Penido C. Natural heat shock protein 90 inhibitors in cancer and inflammation. Eur J Med Chem. 2020;189:112063.","journal-title":"Eur J Med Chem"},{"key":"2335_CR17","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s11033-021-06392-z","volume":"48","author":"A \u00d6zg\u00fcr","year":"2021","unstructured":"\u00d6zg\u00fcr A, Kara A, G\u00f6k\u015fen Tosun N, Tekin \u015e, G\u00f6k\u00e7e \u0130. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines. Mol Biol Rep. 2021;48:3439\u201349.","journal-title":"Mol Biol Rep"},{"key":"2335_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/annonc\/mdv031","volume":"26","author":"N Isambert","year":"2015","unstructured":"Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase. Ann Oncol. 2015;26:1005\u201311.","journal-title":"Ann Oncol"},{"key":"2335_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41391-023-00679-x","volume":"26","author":"L Moya","year":"2023","unstructured":"Moya L, Walpole C, Rae F, Srinivasan S, Seim I, Lai J, Nicol D, Williams ED, Clements JA, Batra J. Characterisation of cell lines derived from prostate cancer patients with localised disease. Prostate Cancer Prostatic Dis. 2023;26:614\u201324.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2335_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"2335_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jcph.2128","volume":"63","author":"RA Pearson","year":"2023","unstructured":"Pearson RA, Wicha SG, Okour M. Drug combination modeling: methods and applications in Drug Development. J Clin Pharmacol. 2023;63:151\u201365.","journal-title":"J Clin Pharmacol"},{"key":"2335_CR22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","volume":"21","author":"W Sun","year":"2016","unstructured":"Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21:1189\u201395.","journal-title":"Drug Discov Today"},{"key":"2335_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/cancers13040669","volume":"13","author":"Y Gilad","year":"2021","unstructured":"Gilad Y, Gellerman G, Lonard DM, O\u2019Malley BW. Drug combination in Cancer Treatment-from cocktails to conjugated combinations. Cancers (Basel). 2021;13:669.","journal-title":"Cancers (Basel)"},{"key":"2335_CR24","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201343.","journal-title":"Oncotarget"},{"key":"2335_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmch.2014.11.002","volume":"54","author":"N Chessum","year":"2015","unstructured":"Chessum N, Jones K, Pasqua E, Tucker M. Recent advances in cancer therapeutics. Prog Med Chem. 2015;54:1\u201363.","journal-title":"Prog Med Chem"},{"key":"2335_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/pharmaceutics13091353","volume":"13","author":"NS Nor Hisam","year":"2021","unstructured":"Nor Hisam NS, Ugusman A, Rajab NF, Ahmad MF, Fenech M, Liew SL, Mohamad Anuar NN. Combination therapy of Navitoclax with Chemotherapeutic agents in Solid tumors and Blood Cancer: a review of current evidence. Pharmaceutics. 2021;13:1353.","journal-title":"Pharmaceutics"},{"key":"2335_CR27","doi-asserted-by":"publisher","first-page":"13751","DOI":"10.3390\/ijms232213751","volume":"23","author":"M Langendonk","year":"2022","unstructured":"Langendonk M, Smit NAM, Plattel W, Diepstra A, Meerten TV, Visser L. Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. Int J Mol Sci. 2022;23:13751.","journal-title":"Int J Mol Sci"},{"key":"2335_CR28","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/cncr.29339","volume":"121","author":"R Seggewiss-Bernhardt","year":"2015","unstructured":"Seggewiss-Bernhardt R, Bargou RC, Goh YT, Stewart AK, Spencer A, Alegre A, Blad\u00e9 J, Ottmann OG, Fernandez-Ibarra C, Lu H, Pain S, Akimov M, Iyer SP. Phase 1\/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 2015;121:2185\u201392.","journal-title":"Cancer"},{"key":"2335_CR29","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1200\/JCO.2014.59.7328","volume":"33","author":"ML Johnson","year":"2015","unstructured":"Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ. Phase I\/II study of HSP90 inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer with Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33:1666\u201373.","journal-title":"J Clin Oncol"},{"key":"2335_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.19.00816","volume":"38","author":"RN Pillai","year":"2020","unstructured":"Pillai RN, Fennell DA, Kovcin V, Ciuleanu TE, Ramlau R, Kowalski D, Schenker M, Yalcin I, Teofilovici F, Vukovic VM, Ramalingam SS. Randomized Phase III Study of Ganetespib, a heat shock protein 90 inhibitor, with Docetaxel Versus Docetaxel in Advanced Non-small-cell Lung Cancer (GALAXY-2). J Clin Oncol. 2020;38:613\u201322.","journal-title":"J Clin Oncol"},{"key":"2335_CR31","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1158\/1078-0432.CCR-20-1306","volume":"26","author":"DA Fennell","year":"2020","unstructured":"Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y, Hackshaw A, Wheeler GM. Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in patients with Pleural Mesothelioma (MESO-02): a phase ib trial. Clin Cancer Res. 2020;26:4748\u201355.","journal-title":"Clin Cancer Res"},{"key":"2335_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1042\/BCJ20210854","volume":"479","author":"L Lossi","year":"2022","unstructured":"Lossi L. The concept of intrinsic versus extrinsic apoptosis. Biochem J. 2022;479:357\u201384.","journal-title":"Biochem J"},{"key":"2335_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.15171\/apb.2019.024","volume":"9","author":"R Jan","year":"2019","unstructured":"Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted Cancer therapeutics. Adv Pharm Bull. 2019;9:205\u201318.","journal-title":"Adv Pharm Bull"},{"key":"2335_CR34","doi-asserted-by":"publisher","first-page":"BSR20180992","DOI":"10.1042\/BSR20180992","volume":"39","author":"X Xu","year":"2019","unstructured":"Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39:BSR20180992.","journal-title":"Biosci Rep"},{"key":"2335_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"2335_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/ijo.2014.2727","volume":"46","author":"M Mori","year":"2015","unstructured":"Mori M, Hitora T, Nakamura O, Yamagami Y, Horie R, Nishimura H, Yamamoto T. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. Int J Oncol. 2015;46:47\u201354.","journal-title":"Int J Oncol"},{"key":"2335_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D\u2019Arcy","year":"2019","unstructured":"D\u2019Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43:582\u201392.","journal-title":"Cell Biol Int"},{"key":"2335_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00001813-199402000-00001","volume":"5","author":"LA Smets","year":"1994","unstructured":"Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs. 1994;5:3\u20139.","journal-title":"Anticancer Drugs"},{"key":"2335_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00048059","volume":"11","author":"JA Hickman","year":"1992","unstructured":"Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121\u201339.","journal-title":"Cancer Metastasis Rev"},{"key":"2335_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3892\/ijmm.2016.2482","volume":"37","author":"X Liu","year":"2016","unstructured":"Liu X, Chen S, Tu J, Cai W, Xu Q. HSP90 inhibits apoptosis and promotes growth by regulating HIF-1\u03b1 abundance in hepatocellular carcinoma. Int J Mol Med. 2016;37:825\u201335.","journal-title":"Int J Mol Med"},{"key":"2335_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/ijo.2014.2399","volume":"45","author":"X Wang","year":"2014","unstructured":"Wang X, Chen M, Zhou J, Zhang X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (review). Int J Oncol. 2014;45:18\u201330.","journal-title":"Int J Oncol"},{"issue":"8","key":"2335_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12032-023-02107-5","volume":"40","author":"D Karademir","year":"2023","unstructured":"Karademir D, \u00d6zg\u00fcr A. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells. Med Oncol. 2023;40(8):234.","journal-title":"Med Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02335-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T09:17:58Z","timestamp":1711617478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02335-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02335-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors agree with the publication of this manuscript in this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}